The Latest Cardiac and Vascular News
DALLAS & SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the University of Miami Miller School of Medicine and co-sponsored by the company. The results showed a […]
HOUSTON & SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the trial design for its pivotal Phase III CardiAMP Heart Failure Trial will be presented tomorrow during the “Heart Failure: The Big Target for CV Regenerative Therapy […]
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, with clinical programs in heart failure and sub-acute infarction, today announced the issuance of United States Patent No. 9,301,975 relating to a method of producing mesenchymal stem cells from bone marrow cells in […]
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced completion of treatment for the 10-patient roll-in cohort for the pivotal Phase III CardiAMP Heart Failure Trial. A pre-specified review of the 30-day outcomes in this cohort by the Data […]
